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Abstract: Latanoprost is a prostaglandin F2-alpha isopropyl ester prodrug which is rapidly 
hydrolyzed by esterases in the cornea to the biologically active latanoprost acid. When latanoprost 
is topically administered into the eye, the cornea seems to act like as a slow-release depot to the 
anterior segment. One hour after administration maximum concentration is found in the iris, 
followed by the anterior chamber and the ciliary body. Despite extensive research, controversy 
remains about the real mechanism of action of this drug. Immunohistochemical data have shown 
that the intraocular pressure (IOP) reduction with topical prostaglandin F2-alpha is associated 
with a reduction of collagens within the uveoscleral outﬂ  ow pathway. Evidence from several 
experimental and clinical studies suggests that latanoprost is a valuable addition ﬁ  rst-line treat-
ment alternatives for glaucoma, ocular hypertension and even angle-closure glaucoma. Strong 
points are its efﬁ  cacy, which is demonstrated to be higher than that of brimonidine, dorzolamide 
and timolol with fewer systemic adverse effects; a convenient administration schedule; and the 
IOP-controlling pattern, which is relatively ﬂ  at compared with timolol and dorzolamide, and 
enables better control in glaucoma progression, since large ﬂ  uctuations may be associated with 
the risk of developing glaucoma in untreated ocular hypertensive subjects.
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Introduction
Glaucoma is the second leading cause of irreversible vision loss in the world, 
responsible for approximately 15% of blindness worldwide, and it is estimated 
that 6.7 million of the 67 million people affected by glaucoma worldwide are bilaterally 
blind (Quigley 1996). Glaucoma is a family of diseases not exactly deﬁ  ned by a speciﬁ  c 
intraocular pressure (IOP), but rather as an optic neuropathy that can occur with any 
IOP, depending on the susceptibility of the optic nerve.
Optic nerve damage is indeed not always related to a high IOP value: some patients 
show optic nerve damage with a relatively low IOP (normal-tension glaucoma), while 
others with persistent and pronounced IOP elevation (ocular hypertension) may never 
show such damage. These observations suggest that additional factors, such as vascular 
abnormalities and perfusion pressure, may play an important role in glaucomatous 
damage progression (Quaranta et al 1994).
Several variants of glaucoma exist, classiﬁ  ed according to their etiology (ie, con-
genital, primary or secondary), but the main types are open-angle glaucoma (the most 
prevalent form in Caucasian and African populations) and angle-closure glaucoma 
(the most prevalent form among Asian and Eskimo populations).
Glaucoma incidence rises signiﬁ  cantly with age: population studies show a dramatic 
rise in its prevalence after the age of 40. Furthermore, only one half of the patients 
have been diagnosed (Wensor et al 1998).Clinical Ophthalmology 2008:2(4) 898
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Despite significant surgical and laser parasurgical 
progress, lowering IOP with topical drugs remains the 
initial and probably main treatment for most patients, 
including those with normal-tension glaucoma or ocular 
hypertension.
Latanoprost was introduced in the US in 1996 as the ﬁ  rst 
prostaglandin-based IOP-lowering medication, receiving 
Food and Drug Administration approval between August 
2000 and March 2001.
Mechanism of action
Latanoprost is a prostaglandin F2-alpha isopropyl ester pro-
drug (17-phenyl substituted PGF2-alpha), which is rapidly 
hydrolyzed by esterases in the cornea to a biologically active 
latanoprost acid; this undergoes a ﬁ  rst metabolization passage 
in the liver (mainly though a b-oxidation process) before being 
excreted into urines and feces; the main metabolite in urines 
and feces was identiﬁ  ed as the 1,2-dinor acid of latanoprost; 
furthermore, a more polar fraction from urine was identiﬁ  ed 
as the 1,2,3,4-tetranor metabolite of the latanoprost acid.
When latanoprost is topically administered into the eye, 
the cornea seems to act like a slow-release depot to the 
anterior segment. One hour after administration maximum 
concentration is found in the iris, followed by the anterior 
chamber and the ciliary body. Elimination half-life from these 
tissues is 3 to 4 hours, although trace amounts can still be 
detected 24 hours after subministration. Analysis shows that 
latanoprost does not reach the posterior segment of the eye, 
being detectable only in more anterior tissues.
Despite extensive research, controversy remains about 
the real mechanism of action of this drug. Immunohis-
tochemical data have shown that the IOP reduction with 
topical PGF2-alpha is associated with a reduction of col-
lagens within the uveoscleral outﬂ  ow pathway. The ciliary 
body contains several prostaglandin receptors (mainly FP 
and EP2 receptors), whose activation seems to stimulate a 
second messenger cascade for metalloproteinases synthesis 
(metalloproteinases are enzymes involved in extracellular 
matrix remodeling).
Ocklind (1998) treated human ciliary muscles with 
latanoprost for 1 to 2 days and then immunoassayed them 
against various extracellular matrix components and 
metalloproteinases. In response to latanoprost, collagen I, III, 
IV, ﬁ  bronectin, laminin and hyaluronan were reduced, while 
metalloproteinases 2 and 3 were upregulated. These ﬁ  ndings 
conﬁ  rm a role for latanoprost in remodeling the extracellular 
matrix in order to allow an easier outﬂ  ow of the aqueous 
humor through the ciliary muscle bundles.
This does not seem to be the only way latanoprost 
acts in lowering IOP: Sharif et al (2003) showed that 
prostaglandin analogs stimulate the prostaglandin FP recep-
tors of human trabecular cells in vitro and this could increase 
matrix metalloproteinases within the meshwork and change 
the extracellular matrix, similar to the effect proposed 
for the uveoscleral pathway. Lim et al (2008) studied the 
effects of prostaglandin analogs on aqueous dynamics and 
found that they reduce the IOP by increasing the outﬂ  ow 
either by the trabecular or the uveoscleral pathway, although 
which is the main pathway depends on the measurement 
technique used.
The most certain assumption is that latanoprost acts 
without significantly affecting the aqueous production 
rate, which could be an important property when used in 
combination (also ﬁ  xed combinations) with other agents 
that reduce aqueous production (ie, β-blockers or carbonic 
anhydrase inhibitors).
Efﬁ  cacy
Starting from the early years of treatment, clinical evidence 
showed that the best IOP control is achieved with one 
subministration of latanoprost per day rather than two 
(Nagasubramanian at al 1993). The reason for this is not 
fully clear, but is probably related to a down-regulation 
or a receptor subsensitivity that causes the loss of effect 
(Linden et al 1998).
After a single topical dose of latanoprost 0.005%, IOP 
reduction is maximal within 8 to 12 hours and IOP remains 
below pretreatment level for at least 24 hours. In 24-hour 
IOP measurements, latanoprost administered once a day 
in the evening induces a constant IOP reduction, although 
the hypotensive effect seems to be greatest during the day 
(Quaranta et al 2006).
In patients with glaucoma or ocular hypertension 
(IOP  21), a number of studies, between 1 and 12 months’ 
treatment, report a reduced IOP level, from 22% to 39% 
(Perry et al 2003).
A meta-analysis of randomized clinical trials widely 
estimated the IOP reduction achieved by the most frequently 
prescribed glaucoma drugs and a placebo and pointed out 
that prostaglandin analogs are the most effective group 
for lowering IOP by monotherapy in primary open angle 
glaucoma (POAG) or ocular hypertensive patients, with a 
relative change of −31% (at peak) and −28% (at trough) for 
latanoprost (Van der Valk et al 2005).
After a long-term treatment, since latanoprost has 
no clinically signiﬁ  cant effect on the permeability of the Clinical Ophthalmology 2008:2(4) 899
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blood–aqueous barrier, IOP will return to pretreatment levels 
within a few weeks, indicating that latanoprost is safe for 
long-term treatments (Linden et al 1997).
Comparative studies
Timolol
Several trials report that latanoprost is signiﬁ  cantly more 
effective than timolol (timolol 0.5% administered twice 
daily) in reducing mean diurnal IOP and, while timolol 
maintains the same effects after 2 weeks of treatment, 
latanoprost has a further, significant, IOP reduction 
from 2 weeks to 6 months (Alm et al 1995; Camras et al 
1996; Hedman et al 2000). This more consistent effect of 
latanoprost, in comparison with timolol, is more uniform 
and predominantly obtained during the night, probably 
because the rate of aqueous humor ﬂ  ow is lower during 
sleep and timolol, in contrast to latanoprost, acts on the 
production of humor ﬂ  ow rather than on the outﬂ  ow (Reiss 
et al 1984).
In patients under timolol therapy, a signiﬁ  cantly greater 
reduction in diurnal IOP can be achieved after addition of 
latanoprost to timolol monotherapy, although switching to 
latanoprost monotherapy could be attempted before starting 
combination treatment (Bucci 1999).
A latanoprost–timolol ﬁ  xed combination, which has 
the advantage of a more convenient delivery system as 
well as providing a simple summing effect of the two 
constituents, is available on the market. Two studies 
show that this ﬁ  xed combination of 0.005% latanoprost 
and 0.5% timolol, administered once daily in the morning 
for 6 months, is more effective in reducing IOP than 
the individual components alone (Pfeiffer et al 1996; 
Higginbotham et al 2002).
A meta-analysis by Webers et al (2006) pointed out that 
the concomitant use of 0.005% latanoprost and 0.5% timolol 
gave a change from baseline of −6.0 mmHg (−6.8 to −5.2) 
at the mean diurnal curve, while the ﬁ  xed combination 
of 0.005% latanoprost and 0.5% timolol resulted in a 
mean change of −3.0 mmHg (−3.8 to −2.2) at the mean 
diurnal curve. This large difference can be explained by 
an omission of the timolol evening dose or by the different 
peak effect of latanoprost, timed 12 hours from the point 
of dosing (not 2 hours as for timolol), whereas the studies 
analyzed in this meta-analysis mostly measured IOP 0, 2 and 
8 hours after the drops were used.
Pillunat in 2003 pointed out that latanoprost monotherapy 
is also a safe and effective alternative for those patients with 
open angle glaucoma under dual topical ocular hypotensive 
therapy, with a beta adrenergic receptor antagonist as one 
of the two components.
Dorzolamide
O’Donoghue et al (2000), in a study sample of 224 patients 
with open angle glaucoma or ocular hypertension, found that 
latanoprost was superior to dorzolamide 2% (3 times a day) 
in reducing IOP, judged both from the effect on IOP at peak 
and trough and by the effect on diurnal IOP. Quaranta et al 
(2006) found a similar extent reduction at all time points 
between 10 PM and 6 AM, which became a higher reduction 
in favor of latanoprost if the mean circadian IOP pressure 
value was considered.
Timolol–dorzolamide fixed combination (TDCF) 
administered twice daily gives a lower 24-hour pressure 
(p = 0.004) and equally enhances 24-hour diastolic ocular 
perfusion pressure (DOPP) in previously untreated POAG 
patients compared with latanoprost (Quaranta et al 2008a). 
On the other hand, García Sanchez (2000), in the Spanish 
Latanoprost Study Group, found a 1.2 mmHg statistically sig-
niﬁ  cant difference in IOP reduction in favor of latanoprost.
Brimonidine
Latanoprost, in a meta-analysis of randomized trials, was 
statistically more effective than brimonidine 0.2% twice 
daily as monotherapy in lowering IOP (Fung et al 2007). 
Furthermore, brimonidine is less effective than latanoprost 
in increasing DOPP (Quaranta et al 2006), since latanoprost 
does not affect systemic blood pressure as does brimonidine, 
which remains a selective α2-agonist and is associated with 
a higher rate of fatigue.
Bimatoprost
Although a little controversy still remains about the 
comparison of latanoprost with bimatoprost 0.03% 
(administered once daily), studies show that their IOP 
reduction is very similar similar. Simmons et al (2004) 
found greater IOP lowering with bimatoprost, ranging from 
0 to 1.5 mmHg, which was not always statistically signiﬁ  -
cant at all time-points but, according to the Early Manifest 
Glaucoma Trial, could be clinically signiﬁ  cant in reducing 
the risk of progression in patients with glaucoma. In another 
study, Gandolﬁ   et al (2001) reported that bimatoprost pro-
vided lower mean pressures than latanoprost at every time 
point throughout the study and was statistically superior 
in achieving low target pressures. In both studies mild 
conjunctival hyperemia was the most frequently reported 
adverse effect associated with either drug, but occurred more Clinical Ophthalmology 2008:2(4) 900
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frequently with bimatoprost. In a recent study on normal 
tension glaucoma (NTG), Quaranta et al (2008b) showed that 
latanoprost and bimatoprost achieve a similar 16% extent in 
IOP lowering, which differs from the 32% reduction found 
in the Gandolﬁ   study, probably because of the lower baseline 
pressure in NTG patients.
Pilocarpine
Latanoprost monotherapy is at least as effective as the 
twice-a-day ﬁ  xed timolol–pilocarpine combination treatment 
in reducing mean diurnal IOP (Nordmann et al 2000).
Despite initial assessments in animals (Crawford et al 
1987) showing that high concentrations of cholinergic agonists 
reduced drainage through uveoscleral pathway and attenuated 
the effects of a PGF2-alpha, Toris et al (2002) showed that 
while latanoprost increases uveoscleral outﬂ  ow, pilocarpine 
increases outﬂ  ow facility and pilocarpine does not block 
or attenuate the uveoscleral outﬂ  ow effect of latanoprost, 
with a greater IOP reduction when these drugs are used in 
combination than when either drug is used alone. Kent et al 
(1999) assessed the order and timing of pilocarpine and latano-
prost administration and found that they could signiﬁ  cantly 
alter their hypotensive activity. Pilocarpine is most effective 
when administered 4 times a day and when the bedtime dose is 
administered 1 hour after the administration of latanoprost.
Angle-closure glaucoma
Some published data report Nd:YAG laser iridotomy as 
an effective therapy in widening the drainage angle and 
reducing elevated IOP in people with primary angle closure 
(Nolan et al 2002; Ahmed 2006). Despite this, medical 
therapy remains the best strategy available for those eyes 
still having uncontrolled IOP after iridotomy. Aung et al 
(2002) recruited 32 Asian patients with chronic primary 
angle-closure glaucoma (CACG), deﬁ  ned as glaucomatous 
optic neuropathy with a compatible visual ﬁ  eld defect and 
at least 6 clock hours of synechial angle closure on gonios-
copy. All patients had previous peripheral iridotomy (PI) 
with IOP  21 mmHg after PI and, after a washout period, 
were randomized to either receive timolol twice a day 
or latanoprost once a day. Compared with baseline, after 
2 weeks of treatment the IOP was signiﬁ  cantly reduced from 
a statistics point of view by 8.8 ± 1.1 mmHg (p  0.001) in 
the latanoprost group, and by 5.7 ± 0.9 mmHg (p  0.001) 
in the timolol group. The difference in IOP reduction between 
the two treatment groups was 3.1 ± 1.5 mmHg in favor of 
latanoprost (p = 0.04). A similar difference value (3.0 mmHg) 
was found in a similar study by Chew et al in 2004.
In an analogous population of patients, Chen et al (2007) 
studied the IOP-lowering effects of latanoprost versus 
bimatoprost and found that both drugs achieved a statistically 
signiﬁ  cant IOP reducing effect compared with baseline, but 
there was no signiﬁ  cant difference (p = 0.40) between the 
two groups. In a similar study carried out in 2006, they also 
assessed latanoprost versus travoprost, ﬁ  nding a small but not 
signiﬁ  cant (p = 0.19) difference in IOP reduction (0.7 mmHg) 
in favor of latanoprost.
In a comparison of latanoprost monotherapy and 
combined therapy of 0.5% timolol and 1% dorzolamide 
(unﬁ  xed combination) in CACG in Japanese patients, latano-
prost monotherapy signiﬁ  cantly lowered IOP compared with 
unﬁ  xed combination therapy of 0.5% timolol maleate and 
1% dorzolamide hydrochloride (Sakai et al 2005).
An interesting study was carried out by Aung et al 
(2005) in order to evaluate any relationship between the 
configuration of the drainage angle and IOP-lowering 
efﬁ  cacy of latanoprost in subjects with chronic CACG. The 
efﬁ  cacy of latanoprost was not affected by the degree of 
angle narrowing or extent of synechial angle closure, a result 
that is probably correlated with the mechanism of action of 
latanoprost, which mainly facilitates the uveoscleral outﬂ  ow 
rather than the trabecular one.
Pigmentary glaucoma
Pigmentary glaucoma (PG) is characterized by the liberation 
of pigment from the iris pigment epithelium and its deposition 
on various anterior segment structures including the 
trabecular meshwork, obstructing the physiological aqueous 
pathway. Thanks to latanoprost’s uveoscleral remodeling, 
circumventing the trabecular outflow may be a viable 
alternative in pigmentary glaucoma management.
Mastropasqua et al (1999), in a trial with PG patients 
comparing 0.005% latanoprost applied once daily with 0.5% 
timolol applied twice daily, showed a greater hypotensive 
effect with latanoprost than timolol (p  0.001); furthermore, 
after 3 months latanoprost achieved a persistent ﬂ  attening of 
the diurnal IOP curve.
Steroid-induced glaucoma
The ocular or systemic administration of glucocorticoid can 
increase IOP, depending on individual responsiveness, by 
increasing the aqueous outﬂ  ow resistance via morphological 
and chemical changes in the trabecular meshwork. 
Furthermore it provides a number of modiﬁ  cations in protein 
expression, cytoskeletal organization, extracellular matrix 
deposition, cell shape and immunological cells function Clinical Ophthalmology 2008:2(4) 901
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(Clark et al 1995), although the full mechanism is not yet 
fully understood.
Vetrugno et al (2000) assessed the effect of 0.005% 
latanoprost and 0.50% timolol for the treatment of 
steroid-induced ocular hypertension and found that both 
drugs provide a signiﬁ  cant and stable IOP reduction, without 
any real efﬁ  cacy difference between the two drugs. A similar 
result was also found by Gupta et al (2007) in an experimental 
model of steroid-induced glaucoma in rabbits, in which the 
latanoprost IOP reduction (35.06%) was similar to that for 
timolol (34.21%). Another study conﬁ  rmed the efﬁ  cacy 
of latanoprost in steroid-induced glaucoma, reporting a 
28% pressure reduction (Scherer et al 2000).
Effects on blood ﬂ  ow
The effects of latanoprost on ocular circulation in normal 
or glaucomatous eyes have been widely investigated using 
different methods. Vetrugno et al (1998) evaluated the effect 
on pulsatile ocular blood ﬂ  ow (POBF) of latanoprost in 
12 patients aged 37 to 48; choroidal perfusion was measured 
through Langham’s POBF system during the ﬁ  rst day of 
therapy and then after 7, 15, 30, 60, 90 and 180 days; POBF 
values increased up to 55.8% in the ﬁ  rst day and then settled 
at 22.6% at the end of the study; timolol showed distinctly 
lower blood perfusion values.
A similar positive result was found by Koz et al 
(2007): using color Doppler ultrasound they found a 
statistically signiﬁ  cant lowering of resistive index (RI) in 
the ophthalmic artery after 6 months of latanoprost therapy. 
However, when latanoprost is associated to timolol in a 
ﬁ  xed combination, the blood ﬂ  ow seems to be affected, 
with a signiﬁ  cant decrease in end-diastolic velocity and a 
signiﬁ  cant increase in RI, measured in the posterior ciliary 
arteries (Martinez et al 2007).
Harris et al (2008), using Heidelberg Retinal Flowmetry 
and Color-Doppler imaging measurements (including peak 
systolic velocity and end diastolic velocities), found that 
latanoprost has mostly neutral effects on ocular circulation, 
heart rate and blood pressure in healthy subjects. This is in 
contrast with the results found by Gherghel et al (2008), 
which shows that latanoprost increases mean ocular perfusion 
pressure (MOPP) and improves ocular perfusion at the optic 
nerve head and retina levels, measured with Heidelberg 
Retina Flowmeter system.
DOPP assessment is interesting, since a low DOPP 
(55 mmHg) is associated with an increased prevalence and 
incidence of glaucoma (Quigley et al 2001; Leske et al 2002). 
Latanoprost, in glaucomatous patients, achieves the best 
DOPP increase (+5.7 mmHg) compared to baseline, followed 
by dorzolamide (+5.2 mmHg) and timolol (+2.3 mmHg) 
(Quaranta et al 2006).
Because normal tension glaucoma is supposed to have a 
reduced choroidal perfusion in its pathogenesis, evaluation 
of ocular perfusion is an interesting subject to assess. Zeitz 
et al (2005) showed no signiﬁ  cant alteration in systolic and 
diastolic blood ﬂ  ow velocities in the short posterior ciliary 
artery, assessed by color Doppler imaging 3 to 5 weeks after 
initiation local latanoprost therapy with either latanoprost or 
bimatoprost.
Adverse events
Published data show that latanoprost is generally well 
tolerated and, in contrast to timolol, is associated with 
minimal systemic adverse effects (Patel et al 1996), which are 
mostly mild and reversible on treatment discontinuation.
The most frequent adverse ocular side event was mild 
conjunctival hyperemia, which is a common effect of 
topical prostaglandin treatment (Susanna et al 2001), usually 
occurring within the ﬁ  rst 2 days of treatment and declin-
ing over time. Compared with bimatoprost, conjunctival 
hyperemia is similar or more common with bimatoprost, 
while a light headache is more frequent with latanoprost 
(Dubiner et al 2001; Gandolﬁ   et al 2002).
Latanoprost induces increased iridial pigmentation 
in 11% to 23% patients during a 1-year treatment. The 
highest incidence of induced pigmentation was seen in 
green-brown, yellow-brown and blue/grey-brown eyes. 
Irides, homogeneously blue, grey, green or brown, are 
seldom affected. Typically, a concentric increase of the 
iris pigmentation appears after 6 months of treatment 
(judged to be noticeable by the patient in about two thirds 
of the cases) and, after cessation of latanoprost, increased 
pigmentation persists in patients who have been followed 
for 2 years (Wistrand et al 1997). The pathogenesis of this 
is not completely understood, although a study showed 
that in vitro latanoprost induces tyrosinase activity, rather 
than increasing the mitotic index in any of the human 
melanoma lines studied. This suggests that the in vivo iris 
pigmentation side effect of latanoprost may not result from 
increased cell division, but from elevated tyrosinase activity 
(Dutkiewicz et al 2000).
Latanoprost-treated eyes may develop hypertrichosis 
and increased pigmentation in the region of treatment 
(Johnstone et al 1997). Main changes in eyelash appearance 
include increased number, length, thickness, curvature and 
pigmentation. An increased pigmentation of the eyelid and Clinical Ophthalmology 2008:2(4) 902
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periocular skin has also been reported (Wand et al 2001; 
Inoue et al 2006).
Because latanoprost is prostaglandin-based it may cause 
ocular inﬂ  ammation, although when patients develop anterior 
chamber reaction during latanoprost treatment it seems to be 
caused by a mere alteration of the blood–aqueous barrier and 
not by a real inﬂ  ammatory process (Ardjomand et al 2000). 
An objective study of the aqueous ﬂ  are comparing latanoprost 
with travoprost and bimatoprost showed that after 3 months 
the travoprost (p  0.013) and the bimatoprost groups 
(p  0.001) had less ﬂ  are than the latanoprost group, an 
effect that persisted even after 6 months (Cellini et al 2004). 
This is probably explained by a lightly superior break of the 
blood–aqueous barrier induced by latanoprost.
Smith et al (1999) showed that a mild delayed uveitis 
with latanoprost treatment may develop rarely, while in 
patients with a uveitis history, a mild delayed exacerbation 
potentially may occur and IOP may not be decreased in 
active uveitis.
Clinically symptomatic and angiographically documented 
cystoid macular edema (CME) associated with the use 
of latanoprost in pseudophakic eyes after uncomplicated 
cataract surgery has been reported, but a causal relationship 
between CME and latanoprost has not yet been proved or 
disproved.
Benzalkonium chloride (BAK), the most commonly 
used ocular preservative, has a very important role in the 
main adverse events, such as conjunctival hyperemia, 
decreased tear turnover, tear film break-up time and 
inﬁ  ltration of the cornea by inﬂ  ammatory cells. BAK 
is retained in tissues and can be found up to 168 hours 
after a single drop of 0.01% BAK in rabbits. The half-life 
of BAK in corneal epithelium and conjunctival tissues 
is 20 hours. Furthermore, prolonged exposure to BAK 
causes indirect and direct toxic effects to the ocular 
surface, including infiltration by inflammatory cells, 
reduced cellular viability and compromised epithelial 
barrier function through increased corneal epithelial cell 
permeability (Baudouin et al 2007). The toxic effects 
of BAK are dose-dependent, with progressive, slow, 
cell growth arrest occurring at concentrations as low as 
0.0001%, more rapid apoptosis at 0.01%, and immediate 
epithelial cell necrosis at higher concentrations of 0.05% 
(De Saint et al 2002).
Baudouin et al (2007) investigated, in vitro, prostaglandin 
solutions preserved with BAK and the BAK-free solution 
travoprost Z 0.004%, evaluating their effects on cellular 
viability, membrane integrity, and apoptosis through 
microtitration fluorometric assays and flow cytometry. 
They found that latanoprost with BAK, travoprost with 
BAK, and BAK alone have signiﬁ  cant cytotoxic effects on 
human conjunctiva-derived cells and are associated with 
apoptosis. These effects likely result from the use of BAK 
as a preservative (Baudouin et al 2007).
In an animal model (Kahook et al 2008) changes were 
compared in the number of goblet cells after chronic 
exposure to latanoprost preserved with 0.02% BAK eye 
drops (Xalatan®; Pﬁ  zer, NY, USA), travoprost preserved 
with sofZia® eye drops (Travatan Z®; Alcon, Fort Worth, TX, 
USA), or preservative-free artiﬁ  cial tears. Goblet cells per 
high-power ﬁ  eld were counted after 30 days of once-daily 
topical application: 2.21 (±0.40) in the latanoprost with BAK 
group, 6.02 (±1.20) in the travoprost with sofZia group, and 
7.03 (±1.33) in the preservative-free artiﬁ  cial tear group. 
The number of goblet cells in the latanoprost with BAK 
group was signiﬁ  cantly lower than in the other two groups 
(p = 0.0001).
Another in vivo study, based on a subjective symptom 
score and various clinical tests, supported these in 
vitro findings, showing that eyedrops containing BAK 
were associated with approximately 2-fold higher odds 
showing abnormal results on the lissamine green staining 
test (Leung et al 2008).
The development of ocular preservatives that provide a 
non-toxic alternative to BAK will likely become useful in the 
management of chronic diseases such as glaucoma.
Persistency
As previously reported, the recommended dosage of 
latanoprost is a single drop once a day. This, together with 
its proven efﬁ  cacy and favorable tolerability, is probably 
one of the most important characteristics of this drug, 
which has led to its best compliance and persistency among 
glaucoma medications. In population-based persistency 
studies performed in different geographic regions of the US, 
latanoprost users exhibited the greatest persistency (versus 
β-blockers, betaxolol, carbonic anhydrase inhibitors and 
brimonidine), without discontinuing, switching or adding 
a new class of glaucoma therapy (Dasgupta et al 2002; 
Shaya et al 2002; Spooner et al 2002).
Cost-effectiveness analysis
An economic evaluation of latanoprost cost-effectiveness 
ratio should be considered, since latanoprost, like all other 
glaucoma therapies, is a chronic therapy.Clinical Ophthalmology 2008:2(4) 903
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Prostaglandin analogs for ophthalmic use are more 
expensive than alternative agents for lowering IOP and thus 
they need a careful assessment of their effectiveness.
Lachaine et al (2008) used IOP reduction in millimeters 
of mercury (compared with baseline and the incidence 
of adverse events) as the effectiveness data of the most 
used glaucoma medications, and found that dorzolamide, 
compared with latanoprost, is not a cost-effective 
strategy. Latanoprost, compared with brimonidine, has 
provided a higher IOP reduction with an incremental 
cost-effectiveness ratio, but the additional IOP reduction 
with latanoprost was obtained at a higher cost than the 
average cost per millimeter of mercury reduction obtained 
with brimonidine. Compared with timolol, latanoprost 
had a positive incremental cost-effectiveness ratio 
(Lachaine et al 2008).
Payet et al (2008) assessed the cost-effectiveness 
of latanoprost versus travoprost as single agents for the 
treatment of glaucoma in France and pointed out that 
travoprost demonstrated a longer effectiveness proﬁ  le than 
latanoprost, although travoprost was more expensive than 
latanoprost (additional 5-year costs for travoprost were €51). 
This can be explained by a smaller proportion of patients 
needing a new treatment, laser therapy or surgery in the 
travoprost group, compensating for the higher travoprost 
acquisition cost (Payet et al 2008).
The real cost-effectiveness ratio may change from one 
country to another. For instance, in the UK timolol is more 
cost-effective than latanoprost, whereas in Scandinavia 
latanoprost may be more cost-effective than timolol 
(Stewart et al 2007).
Conclusions
Evidence from reported studies suggests latanoprost to be 
a valuable addition to the ﬁ  rst-line treatment alternatives 
for glaucoma, ocular hypertension and angle-closure glau-
coma. Strong points are efﬁ  cacy, which is demonstrated 
to be higher than that of brimonidine, dorzolamide and 
timolol with fewer systemic adverse effects; the conve-
nient administration schedule; and the IOP-controlling 
pattern, which is relatively ﬂ  at compared with timolol 
and dorzolamide and allows a better control in glaucoma 
progression, since big ﬂ  uctuations may be associated with 
the risk of developing glaucoma in untreated ocular hyper-
tensive subjects. Another important point is the favorable 
effect of latanoprost on blood ﬂ  ow, providing a higher 
diastolic ocular perfusion pressure and thus better protection 
of the retinal nerve cells.
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